Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer by Anderson, T J et al.
Effect of neoadjuvant treatment with anastrozole on tumour
histology in postmenopausal women with large operable breast
cancer
TJ Anderson
1, JM Dixon
2, M Stuart
3, T Sahmoud
3 and WR Miller*
,2
1Department of Pathology, Western General Hospital, Edinburgh EH4 2XU, UK;
2Breast Unit, Western General Hospital, Edinburgh EH4 2XU, UK;
3AstraZeneca, Alderley Park, Cheshire SK10 4TG, UK
Anastrozole is an orally active, non-steroidal aromatase inhibitor which appears effective as neoadjuvant treatment of breast
cancer. Histological changes have been evaluated in biopsies from large, oestrogen-receptor rich, operable breast tumours in
postmenopausal women following 12 weeks of neoadjuvant anastrozole treatment (1 mg (n=12) or 10 mg (n=11)). Of the
23 patients, 18 had a clinical response following treatment. Compared with pre-treatment biopsies anastrozole-treated
specimens displayed decreased cellularity and/or increased ﬁbrosis in 15 tumours; changes in gland formation, nuclear
pleomorphism, or mitoses, in 12 cases; and a reduction in Mib1 score in all tumours. Marked changes in apoptotic scores were
seen following treatment but the direction of effect was inconsistent. In all 17 tumours which were positive for progesterone
receptors before therapy, treatment was associated with reduced staining for progesterone receptors. There was no
consistent effect of treatment on oestrogen-receptor expression. It is concluded that neoadjuvant anastrozole treatment in this
patient group has marked effects on tumour histopathology but these do not always correlate with clinical response.
British Journal of Cancer (2002) 87, 334–338. doi:10.1038/sj.bjc.6600435 www.bjcancer.com
ã 2002 Cancer Research UK
Keywords: neoadjuvant; anastrozole; postmenopausal women; histology; pathology
Although surgery is the most important mode of primary treat-
ment for most breast cancers, neoadjuvant treatment can be a
useful part of the clinical management of many patients. By giving
appropriate drugs before surgery, tumours may shrink such that
less extensive surgery is needed and, in particular, allow breast-
conserving surgery in patients who might otherwise have required
a mastectomy before neoadjuvant treatment (Miller et al, 1999).
Neoadjuvant treatment also provides a valuable opportunity to
study the effect of drugs on a variety of biochemical and histologi-
cal features of the tumour. Whilst chemotherapy is the most
frequent therapy used in the neoadjuvant setting, endocrine ther-
apy has also been evaluated in hormone-sensitive, large, operable
or locally advanced breast cancer (Anderson et al, 1989; Valero et
al, 1989; Leal da Silva et al, 1998).
Anastrozole is a potent, non-steroidal inhibitor of aromatase, the
enzyme responsible for catalysing the conversion of androgens to
oestrogen. The drug markedly suppresses oestrogen levels in post-
menopausal women, in whom peripheral aromatase activity is the
main route of oestrogen production (Miller, 1996; Bajetta et al,
1999). Clinical trials in postmenopausal women with advanced
breast cancer have shown that anastrozole is well tolerated (Buzdar
et al, 1998). When used as second-line therapy in patients who
have progressed on tamoxifen treatment, it is signiﬁcantly superior
to megestrol acetate in terms of overall survival (Buzdar et al,
1998). In addition, anastrozole has greater efﬁcacy in terms of
prolonged time to progression, compared with tamoxifen, as
ﬁrst-line therapy for patients with advanced breast cancer known
to be hormone receptor-positive (Buzdar et al, 2000; Nabholtz et
al, 2000; Bonneterre et al, 2001), as well as having tolerability
advantages. Thus, anastrozole is now challenging the place of
tamoxifen as ﬁrst-line treatment of advanced breast cancer. Studies
have indicated that anastrozole is also effective in the neoadjuvant
setting, producing clinically important reductions in tumour
volume and mastectomy rates (Dixon et al, 2000).
Although it has been established that anastrozole suppresses
oestrogen levels within the tumour when used for neoadjuvant
treatment (Geisler et al, 1999), the precise mechanisms by which
this oestrogen deprivation exerts its clinical effect are not well
understood. The aims of this study were therefore to determine
the effects of 12 weeks’ treatment with anastrozole on the morphol-
ogy, histological grade, proliferative activity, and steroid receptor
status of breast cancers, in order to gain a greater understanding
of the mode of action of this drug.
MATERIALS AND METHODS
The study was approved by the appropriate ethics committee, and
was conducted in accordance with the ethical principles of the
Declaration of Helsinki. All patients gave written informed consent
before any trial-related procedures were performed.
Patients
The study included postmenopausal women with large, operable,
oestrogen-receptor (ER)-rich (ER shown on the initial core biopsy
to be 480 by histoscore) breast cancer. Postmenopausal status was
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www.bjcancer.comdeﬁned as patients aged 50 years or over who had not menstruated
in the past 12 months, or women of any age with follicle-stimulat-
ing hormone (FSH) levels 440 IU l
71. For inclusion in the study,
patients had to have operable breast cancers 43c m( T 2 43 cm,
T3) or locally advanced breast cancer (T4b). Full demographic
and baseline tumour characteristics of the patients have been
reported previously (Dixon et al, 2000) and are summarized in
Table 1.
Study design
The results presented here are secondary outcomes from a
previously published single-centre study which was designed
primarily to assess the effects of anastrozole on peripheral and
intra-tumour aromatase activity (Dixon et al, 2000). Patients were
randomized in a 1:1 ratio to double-blind neoadjuvant treatment
with anastrozole 1 or 10 mg (once daily) for 12 weeks. Before
anastrozole treatment started, breast tissue was removed by wedge
biopsy to determine variables including baseline morphology,
histological grade, proliferative activity, and steroidal receptor
status. At the end of the 12-week treatment period, tumours were
removed by curative-intent surgery. The tumours removed during
surgery were analysed to determine the effects of treatment on the
above variables.
Assessments
Tumour volume Our previous experience, based on excision
biopsies, has shown that ultrasound measurements are generally
more accurate than calliper or mammographic assessments (Forou-
hi et al, 1994). Therefore, tumour volume was assessed pre-
treatment and at monthly intervals by ultrasound, as previously
described (Dixon et al, 2000). Results were calculated as the
percentage change in volume between measurements made before
treatment and after three months’ therapy. In previous publications
(Bajetta et al, 2000; Zilembo et al, 2000) a reduction of 425% in
tumour volume is taken as evidence of clinical response (assess-
ments made in accordance with the International Union Against
Cancer guidelines). However, in the present study, all tumour
volume reductions were greater than 50%.
Histopathology The histopathological features of the tumour
removed by surgery at the end of the study were compared with
the initial wedge biopsy. Tumour morphology was judged by
comparing changes in cellularity and ﬁbrosis. Histology was also
scored for grading features according to the method described by
Elston and Ellis (1991). This method involves the histological
assessment of three components of tumour morphology: tubule
formation, nuclear pleomorphism and frequency of mitoses, and
an overall tumour grade (1 to 3) is calculated.
Cell proliferation – Mib1 staining Ki67 antigen was assayed,
by measuring the binding of a mouse monoclonal antibody,
Mib1, to the Ki67 nuclear antigen, using sections taken from a
pre-treatment tumour biopsy sample and from a post-treatment
surgical specimen. The percentage of cells staining in a minimum
of 10 representative high-power ﬁelds was used to quantify Mib1
expression (Gerdes et al, 1983).
Apoptotic index Apoptotic (cell death) index was measured
using the TUNEL immunohistochemical technique (Lebat-Moleur
et al, 1998). The index was deﬁned as the number of apoptoses
per 1000 cells and was derived using methodology originally used
to assess mitotic index (Simpson et al, 1992).
Oestrogen and progesterone receptors Oestrogen receptor and
progesterone receptor (PgR) status were assessed by immunohisto-
chemical techniques after microwave antigen retrieval, using ID5
(Dako) for ER status and PG88 (Biogenix) for PgR status. The
results were scored on a scale of 0 to 3 for intensity (with each
successive score denoting increasing intensity), and on a score of
0 to 5 for proportion (with the greatest proportion denoted by a
score of 5); the values were then summed into a category score
with a range of 0 to 8 (Allred et al, 1998).
Statistical methods
The study size was chosen in order to analyse the primary endocri-
nological endpoints. The statistic analyses for pathology parameters
were therefore applied without previous power calculations.
Because numbers of patients in each dose group were small and
there is no a priori reason to believe that pathology responses are
dose-related, analyses have been performed combining the dose
groups (although for information tables and ﬁgures present data
separately).
RESULTS
A total of 12 patients were eligible for analysis in the anastrozole
1 mg group, and a total of 11 patients were available in the
anastrozole 10 mg group.
Histopathological assessments
Marked morphological changes with treatment were evident in
the majority of tumours (15 of 23; 65%). These constituted
both decreased cellularity and increased ﬁbrosis in 11 cases,
and decreased cellularity alone in two; in two tumours there
were only microscopic foci of disease after treatment. All these
effects were taken as evidence of a pathology response. Addi-
tionally, changes in grading characteristics were associated with
treatment in 12 of the tumour pairs. Tubular features were
increased in ﬁve cases, nuclear pleomorphism was decreased
in four, and mitotic index was decreased in ﬁve cases but
increased in one.
The relationship between pathological response and ultrasound
volume change is shown in Table 2. This indicates that pathological
changes with treatment may be observed in tumours that have no
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Table 1 Demographic and baseline tumour characteristics of patients
Anastrozole Anastrozole
1 mg day
71 10 mg day
71
Characteristics (n=12) (n=11)
Age (years) 74.1+8.7 69.6+8.8
Weight (kg) 69.6+9.6 75.7+13.4
Height (cm) 156.3+12.2 158.1+12.2
Tumour stage*
T2 11 (91.7) 9 (81.8)
T3 0 (0) 2 (18.2)
T4b 1 (8.3) 0 (0)
Lymph node metastases 2 (16.7) 1 (9.1)
All values are mean+s.d., except: *number (%).
Table 2 The relationship between clinical and pathological response
Clinical response
550% 450%
Pathological response 2 13
No change 3 5
Total 5 18
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with a major reduction in ultrasound volume also show pathologi-
cal response, ﬁve tumours (of 18) were without evidence of
pathological changes. The median tumour volume reduction in
tumours with a pathological response was 78.3% (range=16.5–
97.5%) and for the no-change category was 67.5% (range=6.4–
94.4%), the difference between the groups was non-signiﬁcant
(P=0.59 by Wilcoxon rank test).
Marker immunohistochemistry
Mib1 staining Measurements of Mib1 expression showed that
treatment with anastrozole was associated with a reduction in
staining score in all cases (Figure 1). The initial levels and degree
of reduction was not signiﬁcantly different in tumours with and
without pathological response.
TUNEL Changes in apoptotic index were noted with treat-
ment (Figure 2). However, the direction of change was not
consistent, decreasing in 12 tumours and increasing in 11
tumours. Furthermore, pattern of change was not related to
pathological response.
Oestrogen and progesterone receptors In terms of effects on ER
expression, treatment was associated with no change in the inten-
sity and proportion of cells staining in 15 cases; in the remaining
eight tumours there were minor changes in category score for
staining parameters, but these were minor and equally increased
or decreased.
Of the 23 tumours, 18 were assessed as being PgR positive
before treatment (Table 3), scoring between category 3 and 8; of
these, 11 (61%) subsequently displayed a pathological response.
Of the ﬁve PgR-negative tumours, four (80%) showed evidence
of pathological response and none changed their PgR status.
However, anastrozole treatment caused a marked reduction in
expression of PgR in 17 of the 18 receptor-positive tumours (in
11 cases this was a total loss). This reduction in expression was
irrespective of pathological response.
DISCUSSION
The results of this study show that neoadjuvant treatment with
anastrozole may have marked effects on histopathological features
within breast tumours. These include changes in histological grad-
ing features, markers of proliferation and cell death, and of PgR
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
80
70
60
50
40
30
20
10
0
%
 
S
t
a
i
n
i
n
g
 
c
e
l
l
s
Pathological response
Baseline Baseline 3 months
Treatment Treatment
3 months
No change
Figure 1 Changes in Mib1 (%) after 12 weeks of treatment with anastrozole (combination of 1 and 10 mg doses) in tumours with a pathological response
to treatment (left panel) and in tumours with no response to treatment (right panel).
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Figure 2 Changes in apoptotic index (%o) after 12 weeks of treatment with anastrozole (combination of 1 and 10 mg doses) in tumours with a patho-
logical response to treatment (left panel) and in tumours with no response to treatment (right panel).
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British Journal of Cancer (2002) 87(3), 334–338 ã 2002 Cancer Research UKexpression. We believe that this range of observation has never
been previously reported for an aromatase inhibitor. It is therefore
important to discuss these ﬁndings in terms of: (1) their relation-
ship to clinical response, (2) their inter-relationships, and (3) a
comparison with the effects of other endocrine agents, most nota-
bly tamoxifen.
Clear pathological responses in terms of reduced cellularity
and/or increased ﬁbrosis were noted in the majority of tumours
(15 of 23; 65%). This high response rate probably reﬂects the
patient selection criterion based on ER-rich tumours. It is,
however, lower than the clinical response frequency in the same
tumours. Furthermore, pathological response only correlated
poorly with clinical response as determined by ultrasound. Thus,
although the majority of tumours that had a substantial volume
reduction with treatment also showed a pathological response
(13 of 18), a minority had an ultrasound response without
evidence of pathological changes. This is perhaps not surprising
since it is possible to visualize a scenario in which tumours shrink
without altering their microscopic morphology. Conversely, most
tumours failing to show a signiﬁcant reduction in tumour volume
were also without evidence of pathological change. Furthermore,
there were two tumours that did not have a signiﬁcant reduction
in tumour volume by ultrasound but yet had a pathological
response. In these particular cases it may be that ultrasound
measurements (which in our hands generally appear to give the
most accurate assessment of tumour burden (Forouhi et al,
1994) did not accurately reﬂect true response. Indeed, calliper
assessments in these particular cases indicated reductions in
tumour size (54 and 99%) which were more compatible with
the small pathological size of the excised lesion (data not shown).
These observations suggest that, in monitoring the response to
endocrine agents, pathological determinants should ideally supple-
ment more traditional clinical tumour measurements.
In addition to changes in cellularity, other pathological features
were altered with treatment in approximately 50% of cases: these
included tubule formation, decreased nuclear pleomorphism, and
decreased mitosis, which occurred both alone or in combination.
This indicates that anastrozole therapy is capable of modulating
cellular populations within individual tumours. Furthermore, these
changes are generally towards a phenotype that is accepted as being
less aggressive.
The effects of treatment with anastrozole on Mib1 expression
were striking and consistent in that the proportion of staining
cells was always less in the treated tumour as compared with
the pre-treatment biopsy. Whilst the degree of reduction varied
widely between different tumour pairs, this was not related to
pathological changes or degree of tumour shrinkage, ER level or
PgR status. It would therefore seem that one of the more impor-
tant mechanisms of action of anastrozole, at least in its chronic
use, is to take tumour cells out of the cycle of division. However,
whether this then translates into a clinical or pathological
response depends on other factors. The practical implication of
these observations is that measurement of Mib1 staining, either
initially or after 3 months’ treatment, is not helpful in predict-
ing/monitoring response. Whether intermediate time-point
measurements would have had more utility is unresolved, but is
worthy of further study. It is interesting to note that whilst we
and others have observed consistent decreases in proliferation
following therapy with aromatase inhibitors (Geisler et al, 2001;
Harper-Wynne et al, 2002), this was not our experience with
tamoxifen (Keen et al, 1997). Tamoxifen treatment could be asso-
ciated with an increase in proliferation markers, particularly in
non-responding tumours. Effects on such markers may be repre-
sentative of an important difference in the mechanism of action
between tamoxifen and aromatase inhibitors.
Changes in apoptotic index were observed with treatment.
However, the direction of change was not consistent and did not
relate to clinical or pathological response or change in Mib1 score.
Assessment of these changes in apoptosis is complicated by the
event being: (1) transient and of low frequency in most breast
cancers, and (2) the result of either a primary response to treat-
ment (successful therapy would increase score) or being
secondary to changes in proliferation (decreased proliferation
would produce a fall in score). Given that the chronology of the
processes of proliferation and apoptosis may differ in individual
tumours, the assessment of apoptosis at a single time-point of 3
months into treatment is almost certainly suboptimal. Given that,
in experimental models, the primary apoptotic response to endo-
crine therapy precedes that of proliferation and may be seen as
early as 2–3 days (Cameron et al, 2000), future studies of neoad-
juvant anastrozole would beneﬁt from the inclusion of tumour
samples early in the treatment protocol. These studies are currently
underway.
The lack of a consistent effect on ER expression observed in this
study is also in agreement with results reported previously with
other aromatase inhibitors (Sasano et al, 1999; Harper-Wynne et
al, 2002). This contrasts with inﬂuences on the PgR, the expression
of which was reduced in all but one case and was totally lost with
treatment in most cases. The results of the present study are similar
to previously reported data on other aromatase inhibitors (Sasano
et al, 1999; Harper-Wynne et al, 2002) and are compatible with the
PgR being an oestrogen-inducible protein. It should be noted that
the decrease in PgR occurred in both tumours, with and without
clinical or pathological response. Lack of clinical or pathological
response is therefore not because the tumour fails to recognize
anastrozole as an oestrogen-depriving therapy. It should be noted
that in this setting, PgR status in the pre-treatment biopsy was
not predictive of clinical or pathological responses: for example,
four of the ﬁve PgR-negative tumours exhibited clear pathological
responses with treatment. The consistent effect of anastrozole in
decreasing PgR staining is further evidence that the drug’s mode
of action differs from that of tamoxifen, which has variable effects
on PgR, including increased expression (Miller, 1996; Miller et al,
1999; Chang et al, 2000). The difference in phenotypic expression
following treatment with tamoxifen and aromatase inhibitors may
have clinical relevance in terms of resistance to treatment and
the choice of subsequent sequence of therapies (Hu et al, 1993;
MacGregor and Jordan, 1998). Interestingly, aromatase inhibitors
have already been shown to be of therapeutic value for many
patients whose tumours have developed resistance to tamoxifen
(Bajetta et al, 1999).
In summary, the neoadjuvant use of anastrozole has been
shown to have clear effects on histological features of breast
tumours. The pathological ﬁndings that anastrozole decreases
the expression of both PgR and Mib1 are particularly striking,
and reﬂect the powerful anti-oestrogenic and anti-proliferative
potential of the drug. However, the present study should be
regarded as a pilot study, and the intermediary mechanisms by
which anastrozole achieves a clinical or pathological response
remain unclear. Further research in this area should include a
larger study population, and samples taken earlier after the start
of treatment.
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Table 3 The relationship between change in progesterone receptors
and pathological response
Receptor positive Receptor negative
Lost Decreased No change No change
Pathological 6 5 0 4
repsonse
No change 5 1 1 1
Total 11 6 1 5
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